Biotech of the Year: Seagen


Seagen, formerly Seattle Genetics, was named BioPharmaDive’s 2020 Biotech of the Year. Per BioPharma Dive:

“Once a tiny, cash-strapped startup…Seagen is the largest biotech in the Pacific Northwest and a widely recognized pioneer of a fast-growing class of targeted cancer medicines. Over the past year, Seagen won Food and Drug Administration approval for its second and third cancer drugs, sending its share price to record highs. Worth $33 billion, Seagen is on the cusp of joining the industry’s top ranks.”